ReviewDiscover oncology2026
Landscape and biogenesis of piRNAs in HBV-associated hepatocarcinogenesis: from repetitive elements to oncogenic circuits.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) is a leading cause of hepatocellular carcinoma (HCC), driving oncogenesis through genomic integration, chronic inflammation, and epigenetic dysregulation. While DNA methylation and histone modifications have been studied extensively, the role of PIWI-interacting RNAs (piRNAs), small non-coding RNAs traditionally linked to germline transposon silencing, remains underexplored in HBV-associated HCC. This review synthesizes emerging evidence that HBV infection remodels the hepatic piRNA landscape through viral integration, hepatitis B virus X protein (HBx)-mediated protein interactions, and inflammation-induced transcriptional rewiring. Reported piRNA changes suggest roles in transposable element derepression, epigenetic silencing of tumor suppressors, post-transcriptional targeting of oncogenic mRNAs, and intercellular communication via exosomes; however, most studies remain correlative and lack direct PIWI-binding validation or mechanistic loss-of-function experiments. We further discuss the translational potential of piRNAs as non-invasive biomarkers for early detection and prognosis, and as therapeutic targets through PIWI inhibition, epigenetic editing, or antisense oligonucleotides. By bridging molecular mechanisms with clinical implications, this review proposes a hypothesis-generating framework in which HBV reshapes the hepatic piRNA landscape through viral integration, HBx-mediated protein interactions, and inflammation-associated epigenetic regulation, thereby providing a strategic foundation for future mechanistic studies, diagnostic development, and therapeutic exploration in HBV-driven hepatocarcinogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.